Beijing Tong Ren Tang Chinese Medicine Co Ltd
HKEX:3613
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (16.7), the stock would be worth HK$8.99 (22% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.7 | HK$7.38 |
0%
|
| 3-Year Average | 16.7 | HK$8.99 |
+22%
|
| 5-Year Average | 16.7 | HK$8.99 |
+22%
|
| Industry Average | 13.9 | HK$7.45 |
+1%
|
| Country Average | 13.9 | HK$7.44 |
+1%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
B
|
Beijing Tong Ren Tang Chinese Medicine Co Ltd
HKEX:3613
|
6.2B HKD | 13.7 | 15.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 59.5 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 50.6 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 16.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 12.1 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 22.3 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 24.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 19.1 | 16.4 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 7.1 |
| Median | 13.9 |
| 70th Percentile | 22.8 |
| Max | 11 983 |
Other Multiples
Beijing Tong Ren Tang Chinese Medicine Co Ltd
Glance View
Beijing Tong Ren Tang Chinese Medicine Co., Ltd. engages in the manufacture, retail and wholesale of Chinese medicine and healthcare products. The company employs 745 full-time employees The company went IPO on 2013-05-07. Along with subsidiaries, it operates its business through three segments. The Hong Kong segment engages in the sale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments through retail outlets as well as wholesale of Chinese medicine products in Hong Kong. The company is also involved in the royalty fee income from overseas entities using the brand of Tong Ren Tang. The Mainland China segment engages in the wholesale of healthcare products in Mainland China and the sole distribution of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd. to customers outside Mainland China. The Overseas segment engages in the retail and wholesale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments in other overseas countries.
